- Home
- EDN vs PGEN Comparison
EDN vs PGEN Comparison
Compare EDN & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EDN | PGEN |
|---|---|---|
| Founded | 1992 | 1998 |
| Country | Argentina | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.5B |
| IPO Year | 2007 | N/A |
Fundamental Metrics
Financial Performance| Metric | EDN | PGEN |
|---|---|---|
| Price | $28.34 | $4.94 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $7.67 |
| AVG Volume (30 Days) | 123.7K | ★ 3.4M |
| Earning Date | 03-10-2026 | 03-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.08 | N/A |
| Revenue | ★ $1,678,118,877.00 | $6,309,000.00 |
| Revenue This Year | $32.93 | $342.78 |
| Revenue Next Year | $24.64 | $478.46 |
| P/E Ratio | $17.95 | ★ N/A |
| Revenue Growth | 3.69 | ★ 59.20 |
| 52 Week Low | $14.38 | $1.11 |
| 52 Week High | $40.26 | $5.23 |
Technical Indicators
Market Signals| Indicator | EDN | PGEN |
|---|---|---|
| Relative Strength Index (RSI) | 45.93 | 58.55 |
| Support Level | $28.06 | $4.41 |
| Resistance Level | $30.39 | $5.00 |
| Average True Range (ATR) | 1.89 | 0.38 |
| MACD | -0.08 | 0.02 |
| Stochastic Oscillator | 31.02 | 90.00 |
Price Performance
Historical ComparisonAbout EDN Empresa Distribuidora Y Comercializadora Norte S.A. (Edenor)
Empresa Distribuidora y Comercializadora Norte SA is engaged in the distribution and sale of electricity. The firm's concession area covers the northern portion of the city of Buenos Aires mainly to residential, commercial, industrial, and public service.
About PGEN Precigen Inc.
Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.